
|Videos|May 3, 2022
Pharmaceutical CEO Leadership: Real-World Evidence
Among the topics discussed at Pharm Exec’s recent RWE roundtable are how the pandemic has served to validate the use of RWE/RWD; the most important features of a real-world data set; and key considerations when selecting an RWD partner.
Advertisement
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
5




